2seventy bio
2seventy bio, spun out of bluebird bio, Inc., focuses on oncology cell therapy and collaborates with Bristol Myers Squibb on Abecma for multiple myeloma.
Company History
2seventy bio was spun out of bluebird bio, Inc., a pioneer in gene and cell therapy. Officially launched in late 2021, the company was established to focus on oncology cell therapy. Since its inception, 2seventy bio has collaborated with notable partners such as Bristol Myers Squibb, Regeneron, Novo Nordisk, and JW Therapeutics. The company made a strategic shift in early 2024 to prioritize resources and capital towards maximizing the potential of Abecma (idecabtagene vicleucel) in multiple myeloma.
Oncology Cell Therapy Focus
2seventy bio specializes in oncology cell therapy, particularly targeting multiple myeloma through CAR T cell therapies. The company's flagship product, Abecma (idecabtagene vicleucel), is being developed in partnership with Bristol Myers Squibb. This focus aligns with the initial mission of bluebird bio, Inc. and has driven 2seventy bio to prioritize its efforts and resources in this therapeutic area.
Strategic Partnerships
The company collaborates with several industry leaders to enhance its oncology cell therapy initiatives. Notable partnerships include Bristol Myers Squibb, Regeneron, Novo Nordisk, and JW Therapeutics. The collaboration with Bristol Myers Squibb, which began in 2013, focuses on developing CAR T cell therapies targeting B cell maturation antigen (BCMA). This partnership has led to the joint development and commercialization of Abecma in the United States, under a Co-Development, Co-Promotion, and Profit Share Agreement.
Key Product: Abecma (idecabtagene vicleucel)
Abecma (idecabtagene vicleucel) is a prominent product in 2seventy bio's portfolio, developed in collaboration with Bristol Myers Squibb. This CAR T cell therapy targets multiple myeloma and is marketed in the United States through a co-development and profit-sharing arrangement. Bristol Myers Squibb is responsible for the drug product's manufacturing and commercialization outside the United States. The strategic focus on Abecma has led 2seventy bio to sell its R&D pipeline to Regeneron, aiming to leverage upfront economics and future royalties to support this key therapy.
Company Locations
2seventy bio operates from two primary locations in the United States. The company's headquarters are located at 60 Binney St., Cambridge, MA 02142. Additionally, there is a significant presence at 188 East Blaine Street, Suite 300, Seattle, WA 98102. These locations support the company's streamlined team of approximately 65 employees in pursuing its mission to advance oncology cell therapy.